Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yishen Qutong Granules Combined With Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer
NCT07390565Enrolling by invitation
- Sponsor
- Lifeng Pharmaceutical
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Randomised, triple-blind trial in small cell lung cancer (SCLC) comparing Treatment group(Yishen Qutong Granules) with Control group(Placebo) (2 arms). Primary endpoint: Disease Control Rate at 540 days. Started Feb 2026; status: enrolling by invitation.
02
Drugs
yishen qutong
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07390565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07390565.